Articles
-
2 months ago |
nature.com | Timothy J Price |Mark McGregor |Laura Depauw |Gabrielle Cehic |Anas Alawawdeh
AbstractMetastatic neuroendocrine neoplasms (mNEN) require new treatment options. Intralesional (IL) PV-10 is an autolytic chemotherapy that may elicit an adaptive immune response. This phase 1 study evaluated IL PV-10 administered percutaneously to hepatic lesions in patients with progressive mNEN. IL PV-10 was injected in a single lesion per treatment cycle. A treatment cycle could be repeated after ≥ 6 weeks if multiple targetable lesions were present. The primary endpoint was safety.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 491
- Tweets
- 4K
- DMs Open
- Yes
RT @Tim_Burgess: Retweet for a chance to win 2 passes for The Charlatans, Embrace & The Coral at Castlefield Bowl in Manchester on July 3rd…
RT @conanriquelme: I am really bad at self-promotion. But I'm proud of these books and wish they had a bigger audience (not coz I get money…
RT @Tim_Burgess: Retweet for a chance to win a Sproston hoodie, T-shirt & sweatshirt On Tuesday May 14th (for 24 hours only) you can orde…
